Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study highlights scale of field trials for bovine TB vaccine
As many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission.
Researchers propose smaller, natural transmission experiments

New research has highlighted the cost and scale of field trials for bovine TB (bTB).

Writing in the journal eLife, researchers show that as many as 100,000 cattle would be needed to show the effect of a vaccine on bTB transmission. They suggest that this scale and cost could be dramatically reduced by using smaller, less expensive experiments.

“We already know that the BCG vaccine has the potential to protect cattle from bovine TB infection,” explains first author Dr Andrew Conlan from the University of Cambridge’s department of veterinary medicine. “Our results highlight the enormous scale of trials that would be necessary to evaluate BCG alongside continuing testing in the field.

“Such trials would be hugely expensive, and it isn’t even clear whether enough farms could be recruited.”

The researchers propose a natural transmission experiment that involves housing a mixture of vaccinated and unvaccinated cattle with a number of infected cattle. They argue that such an experiment could show the efficacy of vaccination, using as little as 200 cattle.

In the UK, the bTB strategy is to ‘test and slaughter’ infected animals. Whilst the BCG vaccine does exist, it can cause some cattle to test positive falsely.

The BCG vaccine is currently banned in Europe. However, the European Union has stated that it would consider relaxing its laws if the UK government could show that a vaccine is effective on farms.

“If we could consider replacing test-and-slaughter with vaccination, then the economics becomes much more attractive particularly in lower income countries,” explained professor James Wood, head of Cambridge’s department of veterinary medicine.

“Then we would no longer need to carry out expensive testing, but could instead rely on passive surveillance through the slaughterhouses.”

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.